Aleix Prat, Director of the Clínic Barcelona Comprehensive Cancer Center, shared on LinkedIn:
“The RIBOLARIS journey continues.
Very happy to see the rationale and trial design of RIBOLARIS now published in Therapeutic Advances in Medical Oncology (Sage Journals).
RIBOLARIS was built around a simple but ambitious question: can we use the biological response of the tumor to neoadjuvant ribociclib + endocrine therapy to identify patients with high-risk HR+/HER2- early breast cancer who may safely avoid chemotherapy?
The trial brings together neoadjuvant therapy, molecular profiling and post-neoadjuvant treatment decisions, using the tumor’s response in vivo to help personalize what comes next.
Importantly, this could also translate into a remarkably simple precision-oncology strategy: for approximately 50% of patients, only 1-2 genomic assessments may be needed to guide treatment de-escalation, without the need for MRD testing or longitudinal molecular monitoring.
This article describes the rationale behind that strategy and the design of a study that has enrolled 1,100 patients.
And this is only the beginning.
The final RIBOLARIS surgical results and Interim Analysis 2 (IA2) outcome are coming soon.
A huge thank you to all the patients, investigators, sites and collaborators who have made this ambitious academic effort possible.”
Title: Rationale and trial design of RIBOLARIS: A phase II trial of neoadjuvant and adjuvant ribociclib plus endocrine therapy for clinically high-risk HR+/HER2-negative breast cancer
Authors: Paul Cottu, Tomas Pascual, Jerôme Lemonnier, Huilin Hu, Estelle Roux, Roisin M. Connolly, Cynthia X. Ma, Antonio C. Wolff, Thayane Crestani, Pablo Tolosa, Juan M. Ferrero-Cafiero, Antonio Mulero-Sánchez, Fernando Salvador, Guillermo Villacampa, Joaquín Gavilá, Thibault de La Motte Rouge, Aleix Prat.
Read the full article.
You can find this interesting: Ribociclib Plus Aromatase Inhibitor Delays Postprogression Events in HR+/HER2− Metastatic Breast Cancer
